Arrowhead






Conservative estimates place the US prevalence at 660 patients. Pie in the sky estimates places the US prevalence at 3,000 patients. Choose between a needle in a haystack and ultra rare.

So a bunch of specialty reps and rare disease journeyman are going to create a market for a drug where most of the discovered patients have already been put on olezarsen? Or is the plan to basically fail until there's a label expansion into prevalent and start of paying specialty salaries now?
 












I put down what I'm worth on the application. It was well above the stated range. I encourage others to do the same. Maybe they'll wake up when they see what real talent is asking. If not, move on.
 






Tell me you didn’t get hired without telling me.
Umm it sounds like that's exactly what they're telling you, genius. This company has some big pharma senior leaders that will make for a very challenging launch in a disease of less than 1000. Not to mention a competitor that is first to market and has been finding patients for years.
 




Talked to a few hiring managers over the last two weeks. All seemed decent, however the comp and territory size is the big issue for me. I was told 170k was the top base and 10k a qtr bonus, this was a four state geo. That same pay is available for a one to quarter of a state geo at plenty of other companies. So if you need a job, take it and keep looking, but long term the money to travel ratio is just not balancing out.

Maybe other geo’s are smaller but I’d get plenty of clarity on geo size before committing. This needs to be a 195-220 base at a bare minimum.
 






In person interviews starting I’ll be curious how far over the 170 people can get. Seems like a pit stop, get a job find the next one while getting paid
I doubt much. 10 years in rare and 5 years selling RNAi to cards. All with significant results. I put down $195 and didn't get a call. They don't want experience. They want cheap.

Good for them. You get what you get.
 





Write your reply...